Episurf presenterer på aksjedagen
http://www.aktiespararna.se/aktiviteter/Evenemang-2016/AktiedagenMalmoSept28/
1 Like
Episurf Medical obtains its first granted patent in Australia (Nasdaq OMX)
2016-09-15 10:15
Episurf Medical is obtaining a granted patent in Australia. The Australian IP
Office has issued a notice of allowance for the patent and has published the
decision on September 15, 2016. This is the first time Episurf obtains a
granted patent in Australia.
This information was published, 2016-09-15 10:15 CEST (GLOBE NEWSWIRE) –
The patent covers a surgical drilling guide with a functionality for depth
adjustments. This guide constitutes a component of Episurf’s toolkit for
implantation of patient specific joint implants.
“To look forward and secure intellectual property protection in new markets is
an important field for an expanding company”, comments Rosemary Cunningham
Thomas, CEO of Episurf Medical.
1 Like
Hadde vært hyggelig om jeg endelig fikk betalt for å ikke selge på alle intradagsrallyene
3 Likes
Episurf Medical to host its first ever educational symposium at the prestigious ICRS Congress in Sorrento, Italy (Nasdaq OMX)
2016-09-21 09:21
An eminent faculty of surgeons and radiologists will lead Episurf Medical’s
first ever educational symposium at the ICRS (International Cartilage Repair
Society) World Congress on Sunday 25th September. The congress is
world-renowned and brings together surgeons and cell biologists who are focused
on treating patients suffering from cartilage pathologies.
This information was published, 2016-09-21 09:21 CEST (GLOBE NEWSWIRE) –
The educational symposium, titled “How to Tailor the Transition between Biology
and Arthroplasty” will be delivered by a panel of four respected clinicians who
specialise in various aspects of cartilage repair. Associate Professor Tim
Spalding, from University Hospitals Coventry and Warwickshire (UK), will chair
the meeting. He will be supported by ex-ICRS President Professor Mats
Brittberg, from Gothenburg (Sweden), Dr Adam Mitchell, from Fortius Clinic,
London (UK) and Professor Leif Ryd, Senior Advisor to Episurf Medical, from
Stockholm (Sweden).
The meeting will discuss the range of options available for treating articular
cartilage lesions of the knee joint and the complexities faced by surgeons. The
session will focus on the place of Episurf’s patented Episealer technology in
the patient treatment algorithm and will include sessions on results, basic
science, the surgical technique and how the MRI processes can be used by a
surgeon to aid their decision making process.
“We are delighted that this world-class group of surgeons and radiologist is
coming together to inform their colleagues about the Episealer technology”,
says Rosemary Cunningham Thomas, CEO of Episurf Medical. “This is a very proud
moment for us. Having these distinguished soft-tissue specialists educating
their colleagues on the science of Epsiealer via their combined clinical
experiences, will help to mainstream Episealer as a valid option in the
surgeon’s treatment algorithm”.
‘’On a daily basis, we see how patients are benefiting from Episealer and we
look forward to working even more closely with surgeons to make a difference
for patient outcomes. The pedigree of the Episealer device for treating
chondral and osteochondral defects will be further supported with the
presentation of 12-month outcome data later in the congress. With a growing
body of impressive clinical outcomes, Episurf Medical is able to meet the
challenges and demands of orthopaedic specialists in the cartilage field”,
concludes Rosemary Cunningham Thomas.
Veldig spennende selskap
[quote]Pioneering mobile training simulation demonstrates groundbreaking technique of
the Episealer patient-specific knee implants, free on iOS and Android.
This information was published, 2016-10-12 08:57 CEST (GLOBE NEWSWIRE) –
Today, Episurf Medical announced the public release of the Episealer surgical
training simulation on the Touch Surgery app. The procedural simulation is now
available to Touch Surgery’s audience of over 1.3 million users globally, which
is a perfect match to the Episealer platform, a proprietary patient-specific
approach to addressing knee lesions and previously untreatable joint pain
problems.
The growing global interest in the groundbreaking Episealer approach to
preserving knee cartilage, is well suited for Touch Surgery’s massive surgical
community. Episurf is committed to providing a high standard of surgical
education and training as surgeons learn the Episealer patient-specific
technique. Touch Surgery’s dynamic and interactive platform enables Episealer
surgeons to practice the surgical technique at a time and place that suits
their hectic surgical schedules.
The Touch Surgery and Episurf Medical teams worked collaboratively to build a
comprehensive training platform that replicates the unique benefits of the
Episealer implant and associated instruments. Three different simulations allow
the user to experience and virtually master the Episealer Condyle Solo,
Episealer Trochlea Solo and Episealer Femoral Twin approaches.
Dr. Jean Nehme MD, co-founder at Touch Surgery, says “We’re honored to have
partnered with Episurf to create a simulation for one of the most innovative
procedures in knee orthopedics, available to anyone, anywhere in the world”.
The global reach Dr. Nehme mentions can be seen in Touch Surgery’s user
population, with users in every country in the world.
“As a young dynamic med-tech company focused on innovation and surgical
education, Episurf Medical immediately recognized the same qualities in Touch
Surgery as a high-end provider of state-of-the-art surgical simulations. It has
been a fruitful partnership and we are delighted with the outcome. Most
importantly, the Touch Surgery platform will give us access to a global
community of orthopedic surgeons previously unavailable to us”, says Rosemary
Cunningham Thomas, CEO, Episurf Medical.[/quote]
Artikkel om dette her. Veldig spennende produkt med støtte for VR og AR
Fantastisk produkt, kjedelig aksje (so far)
Kan problemet være her det samme som i PHO og BIOTEC at forskningen har lykkes, men at investorene undervurderer hvor lang tid det tar å få betydelige inntekter? Da kan slike aksjer bli en ørkenvandring mens man venter på at salget en gang skal ta av.
2 Likes
Prøver meg på 10k til 12.5
1 Like
Inne! 
1 Like
1 Like
Er vel lurt å vente til etter Q3 på fredag med denne?
Tror du den blir dårlig?
Antar det, men ikke noe grunnlag. Bare så vant til at Biotec har dårlige Q rapporter
1 Like
Jeg er inne fordi de har begynt å vise tegn til høyere aktivitet, og det er jo nettopp i kvartalsrapportene at dette kommer frem, derfor tror jeg det er lurt å sitte over disse.
Samtidig er det en ganske liten posisjon, noe som jeg tror er riktig med tanke på at selskapet fortsatt er nærmest uten omsetning og lever på emisjoner, og det vil fortsatt ta et par år før de eventuelt kan nå break-even hvis ikke de blir kjøpt opp eller det kommer en partner som kan aksellerere utviklingen.
Q3 rapport
Tredoblet omsetningen, men til et fortsatt lavt nivå.
https://newsclient.omxgroup.com/cdsPublic/viewDisclosure.action?disclosureId=744324&lang=en
Selve rapporten
2 Likes
Kan se ut som antall operasjoner flatet litt ut i Q3, men det følger vanlig sesongsmønster - det sier nesten seg selv at det er færre operasjoner i fellesferien 
[quote]Following an intense start to the summer months as
measured by the number of Epioscopy™ requests, our
3D-based pre-surgical damage marking process, the
European vacation period, when both surgeons and
patients are away, contributed to slightly lower activity in
August and early September. This is a normal seasonal
occurrence which we anticipated.[/quote]
1 Like
Sykt… må være folk er redde for emisjon, men det bør ligge 3-4 kvartaler borte